1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Lyme Disease Vaccine Pushes Valneva To US Listing

 
• By Jo Shorthouse

Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.

Tick
Ticks carrying Borrelia bacteria cause Lyme disease • Source: Shutterstock

French vaccines company Valneva SE is planning to list on the NASDAQ to fund Phase III studies of the much-needed vaccine for Lyme disease.

The company had a dual listing on the Vienna Stock Exchange and the EuroNext Paris, a legacy from Valneva’s formation through the merger of two publicly listed companies, the Austrian vaccines company Intercell and the French technology company Vivalis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.